

1. Record Nr.	UNINA9911019870603321
Titolo	Molecular cancer therapeutics : strategies for drug discovery and development
Pubbl/distr/stampa	[Place of publication not identified], : Wiley Liss, 2004
ISBN	1-280-55673-0 9786610556731 0-471-65615-1 0-471-65616-X
Descrizione fisica	1 online resource (362 pages)
Disciplina	616.99/4061
Soggetti	Cancer - Chemotherapy Cancer - Immunotherapy Antineoplastic agents - Development Pharmacogenetics Antineoplastic Agents Drug Delivery Systems Drug Evaluation Neoplasms Drug Therapy Evaluation Studies as Topic Therapeutic Uses Disease Pharmacology Genetics Investigative Techniques Pharmacologic Actions Therapeutics Biology Health Occupations Biological Science Disciplines Chemical Actions and Uses Diagnostic Techniques and Procedures Natural Science Disciplines Occupations Oncology Medicine Health & Biological Sciences

Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Bibliographic Level Mode of Issuance: Monograph
Sommario/riassunto	<p>Molecular Cancer Therapeutics covers state-of-the-art strategies to identify and develop cancer drug target molecules and lead inhibitors for clinical testing. It provides a thorough treatment of drug target discovery, validation, and development. The introductory chapters provide an overview of pathways to discovery and development of molecular cancer therapeutics. Subsequent chapters progress from initial stages of drug target discovery to drug discovery, development, and testing in preclinical and clinical models. Topics include drug lead screening, drug-to-lead development, proof-of-concept studies, medicinal chemistry issues, intellectual property concerns, and clinical development. This invaluable reference promotes understanding of steps involved in developing drug leads for industrial partnering and development. It provides an overview of the strategies for discovery and validation of drug target molecules, and discusses cell- and molecule-based drug screening strategies, as well as mouse models for cancer.; Coverage also includes how to refine drug leads for suitability in clinical testing, the special issues of clinical testing of molecular-targeted drugs, and intellectual property concerns.</p>